Apuli Maricel 4

What Happened

• Apuli Maricel, Chief Accounting Officer of BridgeBio Pharma (BBIO), had 4,714 shares of common stock withheld to satisfy tax withholding related to the vesting of RSUs. The withholding was reported as a disposition at $66.13 per share, totaling $311,737.
• The withholding covered taxes on 9,260 vested RSUs, meaning 4,546 net shares remained issuable to Maricel after the tax withholding.

Key Details

• Transaction date: 2026-05-16; Form filed: 2026-05-19.
• Withheld shares: 4,714 at $66.13 each; total value ≈ $311,737.
• Footnote: Withholding (code F) represents shares withheld to satisfy the Reporting Person’s tax obligation on 9,260 vested RSUs.
• Shares owned after transaction: not specified in this filing.
• Filing timeliness: the Form 4 reports the May 16 transaction and was filed May 19 (the filing itself does not state a late-code).

Context

• This was a tax-withholding/cashless action tied to RSU vesting, not an open-market sale — a routine administrative disposition rather than a deliberate sell signal.
• Such withholdings are common when RSUs vest; they reduce the number of shares delivered to the insider and do not necessarily indicate bullish or bearish sentiment.